Death-associated protein kinase 1 is associated with cognitive dysfunction in major depressive disorder

We previously showed that death-associated protein kinase 1 (DAPK1) expression is increased in hippocampal tissue in a mouse model of major depressive disorde and is related to cognitive dysfunction in Alzheimer's disease. In addition, depression is a risk factor for developing Alzheimer's disease, as well as an early clinical manifestation of Alzheimer's disease. Meanwhile, cognitive dysfunction is a distinctive feature of major depressive disorder. Therefore, DAPK1 may be related to cognitive dysfunction in major depressive disorder. In this study, we established a mouse model of major depressive disorder by housing mice individually and exposing them to chronic, mild, unpredictable stressors. We found that DAPK1 and tau protein levels were increased in the hippocampal CA3 area, and tau was hyperphosphorylated at Thr231, Ser262, and Ser396 in these mice. Furthermore, DAPK1 shifted from axonal expression to overexpression on the cell membrane. Exercise and treatment with the antidepressant drug citalopram decreased DAPK1 expression and tau protein phosphorylation in hippocampal tissue and improved both depressive symptoms and cognitive dysfunction. These results indicate that DAPK1 may be a potential reason and therapeutic target of cognitive dysfunction in major depressive disorder.

[1]  Le Qu,et al.  DNA vaccines targeting amyloid-β oligomer ameliorate cognitive deficits of aged APP/PS1/tau triple-transgenic mouse models of Alzheimer’s disease , 2022, Neural regeneration research.

[2]  G. Xing,et al.  Spinal microglial activation promotes perioperative social defeat stress-induced prolonged postoperative pain in a sex-dependent manner , 2021, Brain, Behavior, and Immunity.

[3]  A. Shetty,et al.  Promise of metformin for preventing age-related cognitive dysfunction , 2021, Neural regeneration research.

[4]  A. Hahn,et al.  Neuroplastic effects of a selective serotonin reuptake inhibitor in relearning and retrieval , 2021, NeuroImage.

[5]  F. Lobbezoo,et al.  Oral frailty and neurodegeneration in Alzheimer’s disease , 2021, Neural regeneration research.

[6]  C. Pariante,et al.  Chronic stress followed by social isolation promotes depressive-like behaviour, alters microglial and astrocyte biology and reduces hippocampal neurogenesis in male mice , 2020, Brain, Behavior, and Immunity.

[7]  P. Reddy,et al.  Protective effects of antidepressant citalopram against abnormal APP processing and amyloid beta-induced mitochondrial dynamics, biogenesis, mitophagy and synaptic toxicities in Alzheimer’s disease , 2021 .

[8]  C. Son,et al.  A Comparison of Isolation Stress and Unpredictable Chronic Mild Stress for the Establishment of Mouse Models of Depressive Disorder , 2021, Frontiers in Behavioral Neuroscience.

[9]  Sunghee Kim,et al.  Depression, Loneliness, Social Support, Activities of Daily Living, and Life Satisfaction in Older Adults at High-Risk of Dementia , 2020, International journal of environmental research and public health.

[10]  Jasper A. J. Smits,et al.  Exercise enhances: study protocol of a randomized controlled trial on aerobic exercise as depression treatment augmentation , 2020, BMC Psychiatry.

[11]  Y. Chao,et al.  Simulation study to demonstrate biases created by diagnostic criteria of mental illnesses: major depressive episodes, dysthymia, and manic episodes , 2020, BMJ Open.

[12]  Jing Liu,et al.  Disrupted Structural Brain Network Organization Behind Depressive Symptoms in Major Depressive Disorder , 2020, Frontiers in Psychiatry.

[13]  Matthew O. Parker,et al.  The Free-movement pattern Y-maze: A cross-species measure of working memory and executive function , 2020, Behavior Research Methods.

[14]  Ulrich Dirnagl,et al.  The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research* , 2020, BMC Veterinary Research.

[15]  L. Bernstein,et al.  The Development and Evaluation of a Patient Educational Resource for Cancer-Related Cognitive Dysfunction , 2020, Journal of Cancer Education.

[16]  Yueran Zhao,et al.  TREM2 Overexpression Attenuates Cognitive Deficits in Experimental Models of Vascular Dementia , 2020, Neural plasticity.

[17]  Tiemin Liu,et al.  Impacts of exercise interventions on different diseases and organ functions in mice , 2019, Journal of sport and health science.

[18]  P. Chue,et al.  Effectiveness of Group Cognitive Behavioral Therapy and Exercise in the Management of Major Depressive Disorder: Protocol for a Pilot Randomized Controlled Trial , 2019, JMIR research protocols.

[19]  L. Ercoli,et al.  A Randomized Double-Blind Placebo-Controlled Trial of Combined Escitalopram and Memantine for Older Adults With Major Depression and Subjective Memory Complaints. , 2020, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[20]  O. Aruoma,et al.  Alzheimer’s Disease and Parkinson’s Disease: A Nutritional Toxicology Perspective of the Impact of Oxidative Stress, Mitochondrial Dysfunction, Nutrigenomics and Environmental Chemicals , 2019, Journal of the American College of Nutrition.

[21]  A. Ouanounou,et al.  Medical management, orofacial findings, and dental care for the client with major depressive disorder. , 2019, Canadian journal of dental hygiene : CJDH = Journal canadien de l'hygiene dentaire : JCHD.

[22]  Q. Wang,et al.  The effect of lithium chloride on the attenuation of cognitive impairment in experimental hypoglycemic rats , 2019, Brain Research Bulletin.

[23]  Xiao Zhen Zhou,et al.  Death-Associated Protein Kinase 1 Phosphorylation in Neuronal Cell Death and Neurodegenerative Disease , 2019, International journal of molecular sciences.

[24]  R. McIntyre,et al.  Recognition and Treatment of Cognitive Dysfunction in Major Depressive Disorder , 2018, Front. Psychiatry.

[25]  D. Swaab,et al.  Vulnerability and resilience to Alzheimer’s disease: early life conditions modulate neuropathology and determine cognitive reserve , 2018, Alzheimer's Research & Therapy.

[26]  P. Renshaw,et al.  Living High and Feeling Low: Altitude, Suicide, and Depression , 2018, Harvard review of psychiatry.

[27]  Warren W. Kretzschmar,et al.  Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression , 2017, Nature Genetics.

[28]  Weina Liu,et al.  Swimming exercise reverses CUMS-induced changes in depression-like behaviors and hippocampal plasticity-related proteins. , 2018, Journal of affective disorders.

[29]  M. J. Knight,et al.  Cognitive dysfunction in major depressive disorder , 2018, Current opinion in psychiatry.

[30]  Chuan-zheng Gu,et al.  Predictors of neurocognitive impairment at 2years after a first-episode major depressive disorder. , 2016, Comprehensive psychiatry.

[31]  R. Coveñas,et al.  Serotonergic Drugs: Agonists/Antagonists at Specific Serotonergic Subreceptors for the Treatment of Cognitive, Depressant and Psychotic Symptoms in Alzheimer's Disease. , 2016, Current pharmaceutical design.

[32]  R. Gaillard,et al.  Cognitive Dysfunction in Major Depressive Disorder. A Translational Review in Animal Models of the Disease , 2016, Pharmaceuticals.

[33]  J. Cummings,et al.  Double-blind, placebo-controlled, proof-of-concept trial of bexarotene Xin moderate Alzheimer’s disease , 2016, Alzheimer's Research & Therapy.

[34]  M. Berciano,et al.  Relaunching an old drug: the potential role of bexarotene in neurodegenerative diseases , 2016, Journal of Neurology.

[35]  A. Carvalho,et al.  The Involvement of TNF-α in Cognitive Dysfunction Associated with Major Depressive Disorder: An Opportunity for Domain Specific Treatments , 2015, Current neuropharmacology.

[36]  An Increased Risk of Reversible Dementia May Occur After Zolpidem Derivative Use in the Elderly Population: A Population-Based Case-Control Study: Erratum , 2015, Medicine.

[37]  M. Carrillo,et al.  Summary of the evidence on modifiable risk factors for cognitive decline and dementia: A population-based perspective , 2015, Alzheimer's & Dementia.

[38]  Che‐Chen Lin,et al.  An Increased Risk of Reversible Dementia May Occur After Zolpidem Derivative Use in the Elderly Population , 2015, Medicine.

[39]  C. Sánchez,et al.  Treatment of cognitive dysfunction in major depressive disorder--a review of the preclinical evidence for efficacy of selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors and the multimodal-acting antidepressant vortioxetine. , 2015, European journal of pharmacology.

[40]  A. Carvalho,et al.  Towards a "metabolic" subtype of major depressive disorder: shared pathophysiological mechanisms may contribute to cognitive dysfunction. , 2015, CNS & neurological disorders drug targets.

[41]  Jiu Chen,et al.  Neurocognitive Impairment of Mental Rotation in Major Depressive Disorder: Evidence From Event-Related Brain Potentials , 2014, The Journal of nervous and mental disease.

[42]  A. Kimchi,et al.  Death-associated protein kinase 1 has a critical role in aberrant tau protein regulation and function , 2014, Cell Death and Disease.

[43]  A. Alonso,et al.  Tau-induced Neurodegeneration: Mechanisms and Targets Post-translational Modifi Cation of Tau Tau Phosphorylation Gsk-3 Phosphorylates Tau on ~40 Ser/thr Residues, and Other Post-translational Modifi Cations Mitochondrial Involvement with Tau Therapeutic Approaches Targeting Tau , 2022 .

[44]  Xiang-Shu Cheng,et al.  Phosphorylation of tau by death-associated protein kinase 1 antagonizes the kinase-induced cell apoptosis. , 2013, Journal of Alzheimer's disease : JAD.

[45]  Kevin W Eliceiri,et al.  NIH Image to ImageJ: 25 years of image analysis , 2012, Nature Methods.

[46]  B. Sahakian,et al.  Neurocognitive impairment in adolescent major depressive disorder: state vs. trait illness markers. , 2011, Journal of affective disorders.

[47]  K. Manaye,et al.  Anti-depressant natural flavonols modulate BDNF and beta amyloid in neurons and hippocampus of double TgAD mice , 2010, Neuropharmacology.

[48]  A. Walf,et al.  Progesterone reduces depression-like behavior in a murine model of Alzheimer’s Disease , 2009, AGE.

[49]  Valérie Wilquet,et al.  Amyloid-beta precursor protein processing in neurodegeneration , 2004, Current Opinion in Neurobiology.

[50]  Richard J. Porter,et al.  Neurocognitive impairment in drug-free patients with major depressive disorder , 2003, British Journal of Psychiatry.

[51]  M. Youdim,et al.  Novel neuroprotective anti-Alzheimer drugs with anti-depressant activity derived from the anti-Parkinson drug, rasagiline , 2002, Mechanisms of Ageing and Development.

[52]  A. Heyman,et al.  Head trauma as a risk factor for Alzheimer's disease: a collaborative re-analysis of case-control studies. EURODEM Risk Factors Research Group. , 1991 .

[53]  L. Fratiglioni,et al.  Psychiatric history and related exposures as risk factors for Alzheimer's disease: a collaborative re-analysis of case-control studies. EURODEM Risk Factors Research Group. , 1991, International journal of epidemiology.